Issie Kirby
Stock Analyst at Rothschild & Co
(0.86)
# 3,908
Out of 5,182 analysts
8
Total ratings
25%
Success rate
-3.51%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Issie Kirby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Downgrades: Neutral | $380 → $220 | $182.87 | +20.30% | 2 | Apr 24, 2026 | |
| DXCM DexCom | Upgrades: Buy | $85 → $115 | $59.32 | +93.86% | 2 | Feb 3, 2025 | |
| ALC Alcon | Upgrades: Neutral | n/a | $75.40 | - | 1 | Oct 10, 2024 | |
| TNDM Tandem Diabetes Care | Initiates: Buy | $60 | $18.63 | +222.06% | 1 | May 30, 2024 | |
| COO The Cooper Companies | Upgrades: Buy | $125 | $63.09 | +98.13% | 2 | Mar 19, 2024 |
Insulet
Apr 24, 2026
Downgrades: Neutral
Price Target: $380 → $220
Current: $182.87
Upside: +20.30%
DexCom
Feb 3, 2025
Upgrades: Buy
Price Target: $85 → $115
Current: $59.32
Upside: +93.86%
Alcon
Oct 10, 2024
Upgrades: Neutral
Price Target: n/a
Current: $75.40
Upside: -
Tandem Diabetes Care
May 30, 2024
Initiates: Buy
Price Target: $60
Current: $18.63
Upside: +222.06%
The Cooper Companies
Mar 19, 2024
Upgrades: Buy
Price Target: $125
Current: $63.09
Upside: +98.13%